Mackey Edward F
Known title: EVP, OperationsCIK: 0001632900
Associated companies
Transaction History
| BSX | ▲ Buy | Option Exercise | 2,444 | $0 | 2/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,084 | $48K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,726 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,209 | $51K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,223 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 10,310 | $439K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 23,719 | $0 | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,833 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 832 | $36K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,769 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 813 | $36K | 2/15/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 9,824 | $0 | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 3,068 | $130K | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.